Skip to main content

ANDA (Abbreviated New Drug Application): USFDA Requirements & WHO-GMP Compliance

ANDA (Abbreviated New Drug Application): USFDA Requirements & WHO-GMP Compliance — Full Guide

An ANDA (Abbreviated New Drug Application) is the regulatory pathway for marketing a generic drug in the United States. This guide explains the technical ANDA requirements, eCTD submission structure, alignment with WHO-GMP and ICH principles, common deficiencies, review timelines, and practical best practices you can use in a blog or as an internal reference.

Contents

What is ANDA?

ANDA allows a manufacturer to seek approval to market a generic drug that is pharmaceutically equivalent and bioequivalent to a Reference Listed Drug (RLD). The ANDA applicant demonstrates equivalence primarily through bioequivalence studies and provides complete quality (CMC) documentation—without needing full clinical efficacy trials.

Key Regulatory References

  • USFDA: 21 CFR Part 314 (Drug Applications) and 21 CFR Parts 210/211 (cGMP for finished pharmaceuticals).
  • eCTD: FDA eCTD technical specifications for electronic submissions.
  • GDUFA: Generic Drug User Fee Act — defines user fees and performance goals.
  • WHO-GMP & WHO TRS: Good Manufacturing Practices and relevant WHO Technical Report Series for global GMP alignment.
  • ICH Guidelines: Q1A (Stability), Q7 (API GMP), Q8–Q11 (Pharmaceutical Development and Quality by Design), and M4 (CTD structure).

ANDA Submission Requirements (Technical)

The ANDA must present a scientifically robust dossier covering administrative, quality, non-clinical (if required), and clinical (bioequivalence) information:

Administrative & Regional Documents

  • Form FDA 356h (application form) and cover letter.
  • Applicant establishment information, manufacturing sites, and DMF references (API/excipient DMFs).
  • GDUFA fee confirmation and administrative correspondence.

Quality (CMC) — Module 3 (Detailed)

  • Drug product composition, quantitative formulation, and justification for excipients.
  • Manufacturing process descriptions, batch size, and master & batch production records.
  • Process validation protocol and results (including worst-case runs).
  • Analytical methods and method validation (specificity, accuracy, precision, linearity, robustness).
  • Specifications for drug substance, drug product, and release/stability limits with rationale.
  • Container closure system details and compatibility testing.

Drug Substance (API)

  • API sourcing, synthetic route, impurity profile, and control strategy.
  • Reference to DMF (Type II) or full API dossier, and GMP certification for the API manufacturer.
  • Stability and forced degradation studies to demonstrate degradation pathways.

Stability Data

Stability must follow ICH Q1A(R2) guidance and WHO stability protocols — present long-term and accelerated data, container closure stability, and in-use stability if applicable.

eCTD Structure for ANDA (Module Breakup)

  1. Module 1: Regional administrative information (forms, labeling, patent/certificate info).
  2. Module 2: CTD summaries: quality overall summary, bioequivalence summary, risk assessments.
  3. Module 3: Quality (CMC) — Full technical specifications, methods, validations, and manufacturing data.
  4. Module 4: Nonclinical study reports (rare for classic small-molecule generics but included when applicable).
  5. Module 5: Clinical study reports — Bioequivalence study protocol, statistical analysis plan, raw data, and reports.

WHO-GMP Considerations & Alignment

WHO-GMP provides internationally recognized GMP principles that complement US cGMP. For ANDA applicants with manufacturing sites outside the US, documenting WHO-GMP adherence strengthens the dossier and prepares the site for USFDA inspections.

  • Quality Management System (QMS): SOPs, deviation handling, CAPA, change control.
  • Facility & Utilities: Layout, segregation, HVAC classification, water systems (WFI/purified water), and monitoring.
  • Validation: IQ/OQ/PQ for equipment, process validation, cleaning validation including worst-case residues.
  • Personnel & Training: documented training matrices and competency assessments.
  • Documentation & Records: master batch records, retention samples, audit trails for electronic data.

Bioequivalence & Clinical Expectations

Bioequivalence (BE) demonstrates that the generic delivers the same amount of active drug to the systemic circulation as the RLD. Key technical points:

  • Study Design: usually single-dose, randomized, crossover (healthy volunteers), fasting and/or fed as required.
  • Primary PK Metrics: Cmax and AUC (AUC0-t and AUC0-∞) — 90% confidence interval should fall within 80–125% for most drugs.
  • Statistical Methods: ANOVA and bioequivalence statistics per FDA guidance.
  • Waivers: Biowaivers (based on BCS classification) may be acceptable for certain APIs, reducing the need for in vivo BE studies.
  • Safety & Ethics: GCP compliance, IRB approvals, informed consent, and trial registration where required.

CMC — Critical Documentation & Data (Deep Dive)

Essential CMC elements to prepare robust Module 3 content:

Analytical Procedures & Validation

  • Stability-indicating assays for assay and impurities.
  • Method transfer reports and system suitability criteria.

Impurity & Degradation Profiling

  • Qualification thresholds for impurities and genotoxic impurity assessment.
  • Forced degradation studies to propose degradation pathways and identify potential impurities.

Process Controls & Validation

  • Critical process parameters (CPPs) and critical quality attributes (CQAs) mapping.
  • Robustness studies and worst-case justification for process ranges.

Inspections, Data Integrity & cGMP

USFDA inspections verify cGMP compliance. Prepare the site with mock audits and documented evidence:

  • Data Integrity: ALCOA+ principles — ensure audit trails, controlled user access, and secure backups.
  • Common FDA 483 Observations: inadequate documentation, incomplete investigations, out-of-spec handling, and lack of CAPA closure.
  • Pre-Approval Inspection (PAI): FDA may perform PAI at the manufacturing site prior to final approval; ensure readiness.

Review Timelines & GDUFA Performance Goals

Under GDUFA, FDA sets review performance goals for ANDA reviews. Typical expectations:

  • First cycle review and communications follow GDUFA timelines (applicant receives completeness assessment or deficiency letters).
  • Timelines are subject to application complexity and whether major amendments are submitted.

Common Deficiencies in ANDA Filings (and How to Avoid Them)

  1. Incomplete Stability Protocols: Provide adequate long-term and accelerated data with proper statistical analysis.
  2. Poorly Justified Specifications: Tie release and stability specifications to clinical relevance and impurity safety thresholds.
  3. Inadequate BE Study Design: Ensure study population, sampling, and analysis follow FDA guidance.
  4. Weak Data Integrity Controls: Implement controlled access, electronic records policies, and routine data reviews.
  5. Insufficient Validation: Demonstrate process and cleaning validations with documented acceptance criteria and trending.

Best Practices Checklist (Quick Reference)

  • Prepare a complete eCTD with cross-referenced documents and logical folder structure.
  • Perform mock inspections and gap assessments against FDA and WHO-GMP.
  • Use validated analytical methods and keep method transfer documentation current.
  • Document change control and risk assessments (Quality Risk Management, QRM).
  • Retain stability samples, retain raw data for inspections, and ensure ALCOA+ compliance.

SEO-Friendly FAQs

Q: What is the difference between ANDA and NDA?

ANDA</ is for generics (relies on bioequivalence to an approved RLD). NDA</ is for new chemical entities and requires full clinical data demonstrating safety and efficacy.

Q: When is a DMF required for ANDA?

Reference to an API or excipient DMF (Type II) is used when the API manufacturer does not want to disclose proprietary details; the ANDA should include sufficient cross-reference information and authorization to reference the DMF.

Q: Can a biowaiver be used instead of an in vivo BE study?

Biowaivers based on BCS classification are possible when the API and product meet specific solubility and permeability criteria and the product is rapidly dissolving; justify scientifically per regulatory guidance.

References & Further Reading

Suggested authoritative documents to cite in technical posts or internal SOPs:

  • 21 CFR Part 314 — Applications for FDA Approval to Market a New Drug.
  • ICH M4 — The CTD: Common Technical Document for the Registration of Pharmaceuticals.
  • ICH Q1A(R2) — Stability Testing of New Drug Substances and Products.
  • ICH Q7 — Good Manufacturing Practice for Active Pharmaceutical Ingredients.
  • WHO Technical Report Series (GMP guidance documents).
  • GDUFA Performance Goals & Procedures (for ANDA review timelines).

Popular posts from this blog

Disintegration Time for tablets as per IP, BP and USP

Disintegration Time:- Uncoated Tablet NMT 15 min, in water with Disc 37 0 C ± 2 0 C Coated Tablet NMT 30 min, In water with Disc for Film Coated Tab , and NMT 60 min Other than Film coated tablet Enteric Coated Tab Intact for 2 hr in 0.1 N HCl & disintegrate within 1 hr in Mixed 6.8 Phosphate buffer. According to USP 2 hr in Simulated gastric fluid, then in Simulated Intestinal Fluid. Dispersible/Soluble Within 3 min in water at 25 0 C ± 1 0 C ( IP ) & 15 – 25 0 C ( BP ) Orodispersible Within 1 min Effervescent Tab 5 min in 250 ml water at 20 – 30 0 C ( IP ) & 5  min in 200 ml water at 15-25 0 C ( BP ) Buccal & Sublingual Not Applicable but dissolve within 15 – 30 min. DT Apparatus:- Mesh Apperture:- 2mm (#10), Cycles:- 28 – 32 cycles/min, 50 – 60 mm distance from bottom & top, Temp of water 37 0 C ± 2 0 C. If 1 or 2 tabs fail, repeat for 12 tabs. Click to Buy Here
Read more

Weight variation limit for tablet and capsule.

Weight Variation Limits:- 1) For Tablets  IP/BP.                           Limit.                          USP 80 mg or less.             10%                     130mg or less  80 mg to 250mg.       7.5%               130mg to 324mg 250mg or more.          5%               More than 324mg 2) For Capsule:- IP Limit Less than 300mg 10% 300mg or More 7.5%
Read more

Basics and use of HVAC system in pharma

HVAC is an essential aspect in pharmaceutical industry as factors like temperature, relative humidity and ventilation have a direct impact on the quality of the pharmaceutical product. The designing of the HVAC should be sorted out while design concept of facility is in progress as it is linked to the architectural layouts like air locks, doorways and lobbies. Once the HVAC system is properly designed and installed it not only helps to create the required room pressure differential cascades but also prevents the cross contamination. Basically an HVAC system works by transferring the heat and moisture into and out of the air and controls the level of the air pollutant either by removing them or diluting them to a particular level. TECHNOLOGY OVERVIEW: HVAC system varies according to the size and installation capacity within a facility but the basic components remain almost the same. LAYOUT OF A TYPICAL BASIC HVAC SYSTEM HEATING SYSTEM: The heat source is either a furnace or ...
Read more